“Big money” Positions
In 2018 Q4 United Therapeutics Corp (NASDAQ:UTHR) big money sentiment decreased to 0.85, SEC filings reveal. That’s down -0.17, from 2018Q3’s 1.02. 115 active investment managers opened new or increased equity positions, while 136 trimmed and sold positions in United Therapeutics Corp so the sentiment fall. Funds own 44.07 million shares, up from 40.30 million shares in 2018Q3. Funds holding United Therapeutics Corp in top 10 increased from 3 to 5 for an increase of 2. In total 29 funds closed positions, 107 reduced and 75 increased. Also 40 funds bought new United Therapeutics Corp stakes.
Biggest United Therapeutics Corp Shareholders
Krensavage Asset Management Llc owns 492,660 shares in United Therapeutics Corp as of 2018 Q4. As of 2018 Q4, 1.10 million shares of United Therapeutics Corp are owned by Consonance Capital Management Lp. Great Point Partners Llc reported 350,800 shares. The Virginia-based fund Greylin Investment Mangement Inc have invested about 3.15% of the fund’s stock portfolio in United Therapeutics Corp. The Nebraska-based fund First National Bank Of Omaha looks positive on United Therapeutics Corp, owning 31,991 shares.
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide.The firm is valued at $4.84 billion. The companys product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients.The P/E ratio is 8.26. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy.
UTHR is touching $110.61 during the last trading session, after decreased 0.41%.United Therapeutics Corporation has volume of 271,276 shares. Since March 10, 2018 UTHR has risen 5.78% and is uptrending. UTHR outperformed the S&P 500 by 1.41%.
On May, 1. Investors wait United Therapeutics Corporation (NASDAQ:UTHR) to report its quarterly earnings, according to Zacks. Analysts expect change of 46.32 % or $2.58 from previous year?s $5.57 earnings per share compared to current’s $2.99 earnings per share. In case of $2.99 earnings per share UTHR’s profit could hit $130.73 million. 102.03 % EPS growth is what Wall Street’s forecasts after $1.48 reported EPS last quarter.
Nuwave Mngmt Ltd Liability Co reported 0% in United Therapeutics Corporation (NASDAQ:UTHR). Hanson Mcclain owns 50 shs for 0% of their capital. Utah Retirement Sys holds 7,965 shs. Jpmorgan Chase & owns 0.01% invested in United Therapeutics Corporation (NASDAQ:UTHR) for 333,816 shs. Next Financial Group Inc Incorporated holds 0.01% or 375 shs. California Employees Retirement Sys has invested 0.03% in United Therapeutics Corporation (NASDAQ:UTHR). Signaturefd Ltd Com holds 0.01% or 562 shs. Strs Ohio holds 0% or 492 shs in its capital. Manufacturers Life Insurance Commerce The owns 0.01% invested in United Therapeutics Corporation (NASDAQ:UTHR) for 73,537 shs. Employees Retirement Of Ohio reported 35,642 shs. Arizona State Retirement Systems reported 31,284 shs. Wells Fargo & Mn invested in 395,417 shs or 0.01% of the stock. Dnb Asset Mngmt As has 15,756 shs for 0% of their capital. The Massachusetts-based Fmr Ltd Liability has invested 0.04% in United Therapeutics Corporation (NASDAQ:UTHR). Commerzbank Aktiengesellschaft Fi reported 39,785 shs.
United Therapeutics Corporation had 12 sales and 0 insider purchases since September 6, 2018. This’s net activity of $15.35 million. ROTHBLATT MARTINE A had sold 14,108 shs worth $1.60 million. On Tuesday, February 5 $46,800 worth of stock was sold by Thompson Tommy G.
United Therapeutics Corporation (NASDAQ:UTHR) Ratings Coverage
In total 7 analysts cover United Therapeutics (NASDAQ:UTHR). “Buy” rating has 2, “Sell” are 2, while 3 are “Hold”. (NASDAQ:UTHR) has 29% bullish analysts. 8 are the (NASDAQ:UTHR)’s ratings reports on 10 Mar 2019 according to StockzIntelligence Inc. On Wednesday, February 27 the rating was maintained by Oppenheimer with “Buy”. On Wednesday, February 27 the rating was maintained by Cowen & Co with “Hold”. On Friday, October 12 the rating was upgraded by Standpoint Research to “Buy”. On Monday, November 19 the firm has “Underperform” rating given by Credit Suisse. On Thursday, November 1 Credit Suisse maintained United Therapeutics Corporation (NASDAQ:UTHR) rating. Credit Suisse has “Underperform” rating and $103 target. On Friday, November 2 the firm has “Neutral” rating by JP Morgan given. On Friday, March 1 the firm has “Underweight” rating by Barclays Capital given. On Thursday, February 28 the stock of United Therapeutics Corporation (NASDAQ:UTHR) has “Hold” rating given by Ladenburg.
For more United Therapeutics Corporation (NASDAQ:UTHR) news released briefly go to: Seekingalpha.com, Seekingalpha.com, Nasdaq.com, Nasdaq.com or Investorplace.com. The titles are as follows: “MannKind: Earnings On Tap And Warrants – Seeking Alpha” released on February 21, 2019, “United Therapeutics beats by $0.88, beats on revenue – Seeking Alpha” on February 27, 2019, “Pre-Market Earnings Report for February 27, 2019 : LOW, AMT, TJX, PEG, BBY, AES, CPB, IONS, AMRN, UTHR, LIVN, HPT – Nasdaq” with a publish date: February 26, 2019, “Validea’s Top Five Healthcare Stocks Based On Peter Lynch – 2/17/2019 – Nasdaq” and the last “5 Clinical-Stage Biotech Stocks to Buy – Investorplace.com” with publication date: February 26, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.